Display options
Cite
Buch C, Muller T, Leemput J, et al. Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human. Front Endocrinol (Lausanne). 2021;12:716431doi: 10.3389/fendo.2021.716431.
Buch, C., Muller, T., Leemput, J., Passilly-Degrace, P., Ortega-Deballon, P., Pais de Barros, J. P., Vergès, B., Jourdan, T., Demizieux, L., & Degrace, P. (2021). Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human. Frontiers in endocrinology, 12716431. https://doi.org/10.3389/fendo.2021.716431
Buch, Chloé, et al. "Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human." Frontiers in endocrinology vol. 12 (2021): 716431. doi: https://doi.org/10.3389/fendo.2021.716431
Buch C, Muller T, Leemput J, Passilly-Degrace P, Ortega-Deballon P, Pais de Barros JP, Vergès B, Jourdan T, Demizieux L, Degrace P. Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human. Front Endocrinol (Lausanne). 2021 Aug 09;12:716431. doi: 10.3389/fendo.2021.716431. eCollection 2021. PMID: 34434170; PMCID: PMC8382141.
Copy Download .nbib Format: NLM
Share it on

Front Endocrinol (Lausanne). 2021 Aug 09;12:716431. doi: 10.3389/fendo.2021.716431. eCollection 2021.

Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human.

Frontiers in endocrinology

Chloé Buch, Tania Muller, Julia Leemput, Patricia Passilly-Degrace, Pablo Ortega-Deballon, Jean-Paul Pais de Barros, Bruno Vergès, Tony Jourdan, Laurent Demizieux, Pascal Degrace

Affiliations

  1. Team Pathophysiology of Dyslipidemia, INSERM UMR1231, Université de Bourgogne Franche-Comté, Dijon, France.
  2. Department of Digestive, Thoracic and Surgical Oncology, University Hospital, Dijon, France.
  3. Lipidomic Platform, INSERM UMR1231, Université de Bourgogne Franche-Comté, Dijon, France.
  4. Department of Endocrinology-Diabetology, University Hospital, Dijon, France.

PMID: 34434170 PMCID: PMC8382141 DOI: 10.3389/fendo.2021.716431

Abstract

White adipose tissue (WAT) possesses the endocannabinoid system (ECS) machinery and produces the two major endocannabinoids (ECs), arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). Accumulating evidence indicates that WAT cannabinoid 1 receptors (CB1R) are involved in the regulation of fat storage, tissue remodeling and secretory functions but their role in controlling lipid mobilization is unclear. In the present study, we used different strategies to acutely increase ECS activity in WAT and tested the consequences on glycerol production as a marker of lipolysis. Treating lean mice or rat WAT explants with JLZ195, which inhibits ECs degrading enzymes, induced an increase in 2-AG tissue contents that was associated with a CB1R-dependent decrease in lipolysis. Direct treatment of rat WAT explants with AEA also inhibited glycerol production while mechanistic studies revealed it could result from the stimulation of Akt-signaling pathway. Interestingly, AEA treatment decreased lipolysis both in visceral and subcutaneous WAT collected on lean subjects suggesting that ECS also reduces fat store mobilization in Human. In obese mice, WAT content and secretion rate of ECs were higher than in control while glycerol production was reduced suggesting that over-produced ECs may inhibit lipolysis activating local CB1R. Strikingly, our data also reveal that acute CB1R blockade with Rimonabant did not modify lipolysis

Copyright © 2021 Buch, Muller, Leemput, Passilly-Degrace, Ortega-Deballon, Pais de Barros, Vergès, Jourdan, Demizieux and Degrace.

Keywords: Akt; adipose tissue; cAMP; cannabinoid (CB) receptor 1; endocannabinoid system (ECS); hormono-sensible lipase; lipolysis and fatty acid metabolism; obesity

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Cell Metab. 2010 Apr 7;11(4):242-3 - PubMed
  2. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):515-22 - PubMed
  3. Curr Diab Rep. 2010 Aug;10(4):306-15 - PubMed
  4. Annu Rev Nutr. 2007;27:79-101 - PubMed
  5. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8 - PubMed
  6. Diabetes. 2010 Feb;59(2):375-85 - PubMed
  7. Obesity (Silver Spring). 2010 Nov;18(11):2077-85 - PubMed
  8. Eur J Pharmacol. 2010 Nov 10;646(1-3):38-45 - PubMed
  9. J Clin Endocrinol Metab. 2007 Dec;92(12):4810-9 - PubMed
  10. Int J Mol Sci. 2020 Sep 10;21(18): - PubMed
  11. Gastroenterology. 2012 May;142(5):1218-1228.e1 - PubMed
  12. Diabetes. 2011 Jan;60(1):47-55 - PubMed
  13. Diabetes. 2008 May;57(5):1262-8 - PubMed
  14. Sci Signal. 2012 Mar 20;5(216):ra23 - PubMed
  15. J Clin Endocrinol Metab. 2006 Aug;91(8):3171-80 - PubMed
  16. Endocrine. 2017 Mar;55(3):839-852 - PubMed
  17. Molecules. 2020 Feb 18;25(4): - PubMed
  18. Prog Lipid Res. 2009 Sep;48(5):275-97 - PubMed
  19. Diabetes. 1986 Dec;35(12):1326-31 - PubMed
  20. Front Physiol. 2019 Jan 10;9:1913 - PubMed
  21. Trends Endocrinol Metab. 2018 May;29(5):326-337 - PubMed
  22. PLoS Biol. 2013;11(2):e1001485 - PubMed
  23. Trends Endocrinol Metab. 2014 May;25(5):255-62 - PubMed
  24. Mol Pharmacol. 1984 Nov;26(3):532-8 - PubMed
  25. Int J Biol Sci. 2018 Aug 6;14(11):1483-1496 - PubMed
  26. Br J Pharmacol. 1996 Aug;118(8):2023-8 - PubMed
  27. Obesity (Silver Spring). 2008 Mar;16(3):553-65 - PubMed
  28. Neuron. 2017 Mar 22;93(6):1252-1274 - PubMed
  29. Diabetes Obes Metab. 2015 May;17(5):495-504 - PubMed
  30. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jul;1863(7):712-725 - PubMed
  31. Eur J Pharmacol. 2005 Jul 11;517(3):174-81 - PubMed
  32. Neuropsychopharmacology. 2018 Jan;43(1):155-172 - PubMed
  33. J Lipid Res. 1999 Nov;40(11):2059-66 - PubMed
  34. J Clin Invest. 2017 Nov 1;127(11):4148-4162 - PubMed
  35. J Anim Sci Biotechnol. 2021 Mar 5;12(1):21 - PubMed
  36. Diabetes. 2006 Nov;55(11):3053-60 - PubMed
  37. Diabetologia. 2009 Apr;52(4):664-74 - PubMed
  38. J Neurochem. 2008 Feb;104(4):1132-43 - PubMed
  39. Diabetes Obes Metab. 2010 Feb;12(2):158-66 - PubMed
  40. J Clin Invest. 2003 Aug;112(3):423-31 - PubMed
  41. Obesity (Silver Spring). 2007 Apr;15(4):837-45 - PubMed
  42. Mol Cell Biol. 2015 May;35(10):1686-99 - PubMed
  43. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):51-63 - PubMed
  44. Life Sci. 2005 Feb 4;76(12):1307-24 - PubMed
  45. FASEB J. 2005 Sep;19(11):1567-9 - PubMed
  46. Acta Physiol (Oxf). 2007 Nov;191(3):205-16 - PubMed
  47. C R Biol. 2006 Aug;329(8):598-607; discussion 653-5 - PubMed
  48. Diabetes. 1993 Nov;42(11):1567-73 - PubMed
  49. Diabetes. 2005 Nov;54(11):3190-7 - PubMed
  50. Am J Physiol Endocrinol Metab. 2017 Jul 1;313(1):E26-E36 - PubMed
  51. Diabetes. 2005 Oct;54(10):2838-43 - PubMed
  52. Biochem J. 2000 Apr 15;347(Pt 2):369-73 - PubMed
  53. Int J Obes (Lond). 2020 Nov;44(11):2179-2193 - PubMed
  54. Front Endocrinol (Lausanne). 2016 Apr 13;7:30 - PubMed
  55. J Clin Invest. 2003 Dec;112(12):1796-808 - PubMed
  56. Histochem Cell Biol. 2006 Aug;126(2):177-87 - PubMed

Publication Types